Imre says idiopathic thrombocytopenic purpura (ITP) patients benefit from Prosorba column
This article was originally published in Clinica
Executive Summary
Results from an Imre study reveal the company's Prosorba column may be effective in the treatment of idiopathic thrombocytopenic purpura. The bleeding disorder affects some 300,000 patients in the US and Europe each year.